ABA-101

N/A

Report date: 2024/07/17 11:16:49

Base Information

Drug NameABA-101
Drug Alias NameABA-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbata Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAbata Therapeutics
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A